CONTACTStaffCAREER OPPORTUNITIESADVERTISE WITH USPRIVACY POLICYPRIVACY PREFERENCESTERMS OF USELEGAL NOTICE
© 2024 Pride Publishing Inc.
All Rights reserved
All Rights reserved
By continuing to use our site, you agree to our Private Policy and Terms of Use.
GlaxoSmithKline this week ended all clinical trials of its experimental HIV entry inhibitor aplaviroc after a third study participant developed severe liver toxicity while taking the medication. The company had previously ended one clinical trial arm involving treatment-naive HIV patients when two study subjects in that study developed liver toxicity, but it had allowed trials that included HIV patients who had already taken other antiretroviral drugs to continue. Now all HIV-positive study participants will be switched to other anti-HIV medications, trial researchers say. Aplaviroc was being tested in the United States, Canada, and the European Union. The drug had aimed to jam CCR5 receptors on the surface of immune system cells that HIV must latch onto in order to infect the cells. (Advocate.com)
Want more breaking equality news & trending entertainment stories?
Check out our NEW 24/7 streaming service: the Advocate Channel!
Download the Advocate Channel App for your mobile phone and your favorite streaming device!
From our Sponsors
Most Popular
Meet all 37 of the queer women in this season's WNBA
April 17 2024 11:24 AM
Here are the 15 gayest travel destinations in the world: report
March 26 2024 9:23 AM
21+ steamy photos of Scotland’s finest gay men in Elska Glasgow
February 01 2024 10:07 PM
More Than 50 of Our Favorite LGBTQ+ Moms
May 12 2024 11:44 AM
Conjoined twins Lori Schappell and trans man George Schappell dead at 62
April 27 2024 6:13 PM
Latest Stories
Joe Biden sends queer lawmakers & LGBTQ+ allies to Paris Olympics
July 24 2024 12:08 PM
Kamala Harris rides wave of Democratic energy at kickoff event in Wisconsin
July 23 2024 3:36 PM